In late 2021, Amber Salzman interviewed for a job that she had no intention of taking. A relatively new start-up company, called Epicrispr Biotechnologies, was looking for a chief executive, and it ...
Therapy resistance remains one of the most formidable challenges in oncology. Despite significant advances in targeted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results